Lymphoma Clinical Trials in Los Angeles

Showing 221-240 of 445 trials

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

NCT04338659

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.

Advanced Malignant Tumors Lymphomas

Innovent Biologics (Suzhou) Co. Ltd.22 participantsStarted Jan 2021

Los Angeles, California, United States • Westwood, Kansas, United States • Jackson, Mississippi, United States +1 more locations

COMPLETED< 1 mile

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

NCT01000753

This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.

Adult Immunoblastic LymphomaCentral Nervous System Non-Hodgkin LymphomaChildhood Immunoblastic Lymphoma+10 more

Children's Oncology Group174 participantsStarted May 2005

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +127 more locations

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Lymphoma Trials in Other Cities

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Durvalumab in Pediatric and Adolescent Patients

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Safety Study of SEA-CD40 in Cancer Patients

A Study of BTX-1188 in Subjects With Advanced Malignancies

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Other Conditions in Los Angeles